Tag: GlobeNewswire

Contracted $70 Million Worth of Credits in 2026, Forecasting Production of over $77 Million in Credits for 2027

ENGLEWOOD, Colo., Oct. 01, 2026 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) today announced sales of substantially all of the Section 45Z tax credits generated by its ethanol and renewable natural gas (RNG) facilities in 2026, totaling $70 million worth of credits. Gevo has received over $30 million in cash from these credit sales through September 30 and expects the remaining cash to be received over the next six months. The credits were generated through the production and sale of low-carbon transportation fuels and were sold by Gevo pursuant to the credit’s transferability provisions. 

On September 30, Gevo sold $50 million worth of credits to a non-financial, publicly traded company. Gevo previously sold $20 million worth of credits to Quill Financial, Inc., the parent company of Quill Bank, a Utah-based community bank providing commercial, agricultural, mortgage and consumer banking services.

“We have successfully sold our expected 2026 45Z tax credit position while broadening participation beyond financial institutions to also include strategic corporate buyers,” said Gevo Chief Executive Officer Paul Bloom. “By efficiently monetizing the value generated through our low-carbon fuel operations, we are increasing cash on the balance sheet, enhancing financial flexibility and creating additional value for shareholders.”

Gevo expects to produce an additional $7 to $10 million worth of Section 45Z tax credits in 2027 due to the anticipated completion of debottlenecking activities at Gevo North Dakota that is expected to increase production capacity and associated carbon capture by 10-15%. The debottlenecking remains on track to be completed by the end of 2026.

The 45Z tax credit sales help Gevo to reinvest in low-cost, domestic clean fuel production. These investments support domestic energy security, create jobs in rural America and increase demand for agricultural products grown by U.S. farmers through expanding production and creating long-term shareholder value. As a performance-based credit, 45Z incentivizes investments in efficiency and carbon intensity reduction that enhance the competitiveness of clean fuels and U.S. agriculture.   

About Gevo

Gevo is a next-generation diversified energy company committed to fueling America’s future with cost-effective, drop-in fuels that contribute to energy security, abate carbon, and strengthen rural communities to drive economic growth. Gevo’s innovative technology can be used to make a variety of renewable products, including sustainable aviation fuel (SAF), motor fuels, chemicals, and other materials that provide U.S.-made solutions. Gevo’s business model includes developing, financing, and operating production facilities that create jobs and revitalize communities. Gevo owns and operates an ethanol plant with an adjacent carbon capture and storage (CCS) facility and Class VI carbon-storage well. Gevo also owns and operates one of the largest dairy-based renewable natural gas (RNG) facilities in the United States, turning by-products into clean, reliable energy. Additionally, Gevo developed the world’s first production facility for specialty alcohol-to-jet (ATJ) fuels and chemicals operating since 2012. Gevo is currently developing the world’s first large-scale ATJ facility to be co-located at our North Dakota site. Gevo’s market-driven “pay-for-performance” approach regarding carbon and other sustainability attributes helps deliver value to our local economies. Through its Verity subsidiary, Gevo provides transparency, accountability, and efficiency in tracking, measuring, and verifying various attributes throughout the supply chain. By strengthening rural economies, Gevo is working to secure a self-sufficient future and to make sure value is brought to the market.

For more information, please visit www.gevo.com. 

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, the financial aspects of the 45Z tax credit sales, future 45Z tax credit production and sales, any effects of the 45Z sales transactions on Gevo’s cash flows, gross margin and adjusted EBITDA and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Media Contact
Communications@gevo.com

IR Contact
IR@Gevo.com

Experienced private markets investor joins StepStone following a decade at Japan’s Government Pension Investment Fund

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP), a leading global private markets investment firm, today announced that Yoshitaka Todoroki has joined the firm as a Vice Chairman, focusing on strategic initiatives in Japan and the broader Asia region.

Mr. Todoroki joins StepStone following a distinguished career in private markets investing spanning more than 30 years. Most recently, he served as Executive Director of the Private Market Investment Department at Japan’s Government Pension Investment Fund (GPIF). Throughout his decade-long tenure at GPIF, Mr. Todoroki led the development of the pension fund’s private markets investment program across private equity, infrastructure and real estate. He established its investment strategy and frameworks, risk monitoring and management procedures, and relationships with general partners and other institutional investors globally.

Scott Hart, StepStone CEO, said, “Yoshitaka Todoroki brings tremendous experience and perspective from more than three decades investing across private markets, including helping to build and lead the private markets program for one of the world’s largest institutional investors. His firsthand perspective as an asset-owner and understanding of how investments across private asset classes fit within a broader portfolio will be highly valuable to our clients. We are delighted to welcome him to StepStone as we continue to grow our platform across Asia and beyond.”

Mr. Todoroki said, “Having spent much of my career investing in private markets as an institutional investor, I have long appreciated the importance of strong partnerships, informed judgment and a holistic approach to portfolio construction. StepStone’s deep investment expertise, global perspective and data-driven insights create a powerful platform for serving institutional investors. I am pleased to join the firm and look forward to working with Scott and the broader team to support StepStone’s clients and continued growth in the region.”

Prior to joining GPIF in 2016, Mr. Todoroki was Head of the Alternative Investment Group at Sumitomo Mitsui Asset Management. Earlier in his career, he held investment roles at Sumitomo Mitsui Banking Corporation, MassMutual Life Insurance Japan and The Sumitomo Trust and Banking Co.

Mr. Todoroki holds a Bachelor of Commerce from Hitotsubashi University and completed the Investment Management Programme at London Business School.

About StepStone Group

StepStone Group Inc. (Nasdaq: STEP) is a global private markets investment firm focused on providing customized investment solutions and advisory and data services to its clients. As of June 30, 2026, StepStone was responsible for approximately $913 billion of total capital, including $245 billion of assets under management.

StepStone’s clients include some of the world’s largest public and private defined benefit and defined contribution pension funds, sovereign wealth funds and insurance companies, as well as prominent endowments, foundations, family offices and private wealth clients, which include high-net-worth and mass affluent individuals.

StepStone partners with its clients to develop and build private markets portfolios designed to meet their specific objectives across the private equity, infrastructure, private debt and real estate asset classes.

Contacts

Shareholder Relations:
Seth Weiss
shareholders@stepstonegroup.com
1-212-351-6106

Media:
Jordan Niezelski / Maggie Duffy
Edelman
StepStone@edifi-dje.com

PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland.

Poster details are listed below:

Abstract Title:	Phase 3, randomized, double-blind, placebo-controlled studies of HBS-301 for narcolepsy and idiopathic hypersomnia
Date/Times:	October 2, 16:30 (CEST) October 3, 12:30 (CEST)

About HBS-301 
HBS-301 is an investigational, optimized, high-dose formulation of enteric-coated pitolisant tablets. HBS-301 is being developed in multiple tablet strengths up to 60 mg to treat excessive daytime sleepiness and other symptoms in patients with narcolepsy or idiopathic hypersomnia (IH). HBS-301 is currently being evaluated in two phase 3 clinical trials. The ONSTRIDE-1 study in adult patients with narcolepsy and the ONSTRIDE-2 study in adult patients with IH. 

About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com

LOUISVILLE, Ky., Oct. 01, 2026 (GLOBE NEWSWIRE) — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its third quarter 2026 financial results on Friday, October 30, 2026, prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.

To participate in the conference call, please register here before the 8:30 a.m. ET start. A live and archived webcast of the call will be available on the Company’s investor relations website at https://ir.brightspringhealth.com under the “Events & Presentations” section, where related presentation materials will be posted prior to the conference call. The webcast may be accessed directly here.

About BrightSpring Health Services

BrightSpring Health Services provides complementary home- and community-based health solutions for medically complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care, and rehabilitation, we provide comprehensive and more integrated care and clinical solutions in all 50 states to over 485,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and industry-leading quality metrics across its services lines, while improving the health and quality of life for high-need individuals and reducing overall healthcare system costs.

Contact

Investor Relations:
David Deuchler, CFA
SVP, Strategic Finance & Investor Relations
Executive Director, BrightSpring Health Foundation
david.deuchler@brightspringhealth.com
917.209.5605

Media Contact:
Leigh White
Vice President, Communications & PR
leigh.white@brightspringhealth.com
502.630.7412

• Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the publication of final phase 2a clinical trial results (NCT04495153) of aglatimagene besadenovec (aglatimagene) plus valacyclovir in patients with stage III/IV NSCLC who had shown inadequate response to ICI. The trial demonstrated a median overall survival (mOS) of 24.5 months in the evaluable population, substantially exceeding historical benchmarks for standard-of-care docetaxel chemotherapy in this patient population.

The data is published in the Journal for ImmunoTherapy of Cancer, a leading peer-reviewed oncology journal, providing independent validation of the clinical significance of aglatimagene in patients with advanced NSCLC with an inadequate response to ICI.

Patients with unresectable stage III/IV NSCLC who progress on ICI face limited treatment options and poor survival outcomes. Current standard of care with docetaxel chemotherapy yields a median overall survival of only 9.8 to 11.8 months in this population.^1,2 The phase 2a trial enrolled 46 evaluable patients receiving two courses of aglatimagene plus valacyclovir in combination with continued ICI therapy (per protocol population). Among patients with progressive disease at baseline despite ICI treatment (cohort 2, n=41), mOS was 21.5 months. Notably, 37% of patients with progressive disease on ICI remained alive beyond 24 months at the time of data cutoff, demonstrating a prolonged survival tail not typically observed in this setting.

Non-squamous NSCLC has also emerged as a key predictor of enhanced clinical benefit. In the evaluable population of patients with non-squamous histology and progressive disease on ICI (n=33), mOS reached 25.4 months, with 14 of 15 patients surviving beyond 24 months and 9 of 9 patients surviving beyond 30 months having non-squamous disease. Exploratory analysis in the intention-to-treat cohort of non-squamous patients showed mOS of 16.7 months, still longer than the 12.3-month benchmark reported with docetaxel in this setting in published trials.

Mechanistic studies revealed systemic immune activation following treatment. Among evaluable patients with >1 lesion (n=35), 69% exhibited systemic clinical response with reduction of uninjected lesions, indicating an abscopal response. Biomarker analysis demonstrated increased cytotoxic T cell infiltration in tumor tissue, expansion of activated CD8+ effector and central memory T cells in peripheral blood, and elevated serum levels of granzymes after the second aglatimagene injection, with changes most pronounced following the second administration. Multi-omics factor analysis identified coordinated immune activation patterns associated with improved survival. Patients who survived beyond 24 months exhibited significantly higher levels of key immune markers, including granzyme B and granzyme H, compared to those who died earlier.

Treatment with aglatimagene plus valacyclovir was generally well tolerated, with the most common adverse events being mild flu-like symptoms (fatigue, nausea, pyrexia) that were predominantly grade 1 and 2. Grade 3 treatment-related adverse events were reported in 13.7% of patients. No dose-limiting toxicities or unexpected safety signals were identified during extended follow-up.

“These peer-reviewed results confirm that aglatimagene has the potential to extend survival for patients with advanced non-small cell lung cancer who have limited options after immune checkpoint inhibitors fail to control their cancer,” said Charu Aggarwal, MD, MPH, Leslye Heisler Professor of Medicine at the University of Pennsylvania’s Perelman School of Medicine and lead investigator of the trial. “The magnitude of benefit observed, particularly in patients with non-squamous disease, is striking, and represents an important potential advance for this patient population.”

Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel commented, “Aglatimagene’s ability to reinvigorate anti-tumor immunity in checkpoint-refractory patients through a systemic immune response, combined with its favorable safety profile, positions this approach as a potentially transformative option for patients with limited therapeutic alternatives. These results support the advancement of our pivotal phase 3 AURORA trial, which is enrolling patients globally.”

The global phase 3 AURORA trial is enrolling patients across approximately 150 sites worldwide. The trial is evaluating aglatimagene plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel in patients with metastatic stage IV non-squamous NSCLC who have experienced disease progression despite prior pembrolizumab and platinum-based chemotherapy.

About aglatimagene besadenovec

Aglatimagene, Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Aglatimagene has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several nonclinical and clinical settings. More than 1,000 patients have been dosed with aglatimagene in clinical trials with a favorable tolerability profile to date, supporting the potential for use with standard of care, when indicated. Aglatimagene is currently not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any use.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene) is the lead product candidate from the adenovirus platform. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA and published in The Lancet Oncology. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.

Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat, solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s nonclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com

¹ Paz-Ares LG et al. J Clin Oncol 2024;42:2860-2872
² Ahn MJ et al. J Clin Oncol 2024;43:260-272

• Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.
• Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier.

WASHINGTON, Oct. 01, 2026 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it will disclose the outcome of the interim analysis from its clinical study evaluating tafenoquine in patients hospitalized with severe babesiosis (NCT06207370) on October 6, 2026.

In conjunction with the data release, 60 Degrees will host a Key Opinion Leader (KOL) investor webinar on Tuesday, October 6, 2026. The webinar will highlight the substantial unmet medical need for new therapeutic options in relapsing and treatment-refractory babesiosis, review the clinical data from Company’s hospital and expanded access studies and the literature, and discuss the potential role of tafenoquine in addressing recurrent tick-borne infections.

Webinar Featured Speakers

• Peter J. Krause, M.D., Senior Research Scientist in the Department of Epidemiology and Public Health at Yale School of Public Health and Yale School of Medicine. Dr. Krause is an internationally recognized authority on human babesiosis who led the original antibiotic treatment trial establishing atovaquone/azithromycin as standard-of-care 25 years ago.
• Edouard Vannier, Ph.D., Assistant Professor of Medicine at Tufts Medical Center / Tufts University School of Medicine, a leading clinical researcher specializing in the pathogenesis, diagnosis, and treatment of Babesia microti infection.

During the presentation, the speakers will address the clinical burden of persistent babesiosis in immunocompromised hosts, treatment limitations under current guidelines, and the mechanistic rationale for tafenoquine combination therapy. A live question-and-answer session will follow the presentation.

No FDA-approved treatment or vaccine exists for babesiosis. Tafenoquine is not currently approved by the FDA for the treatment and prevention of babesiosis. Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA® (tafenoquine).

Webinar Details

• Date: Tuesday, October 6, 2026
• Time: 11:00 a.m. ET
• Registration / Webcast Link

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 and currently has active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts

Media Contact:
Kristen Landon
kristenlandon@60degreespharma.com

Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com

Paris, October 1^st 2026, 2:00 p.m.

PRESS RELEASE

Eramet plans to apply under Argentina’s Large Investment Incentive Regime (RIGI) for a first expansion of Centenario-Ratones

• Eramet reaffirms its long-term commitment to Argentina with potential additional investment of around US$350 million in Centenario-Ratones, subject to final investment decision
• Completion of the Pre-Feasibility Study for an initial brownfield expansion, adding 11 kt-LCE per year to the existing 24 kt-LCE annual nameplate capacity
• Planned application for inclusion under Argentina’s Régimen de Incentivo para Grandes Inversiones (RIGI) to support this new investment phase
• A further step in the long-term development of Centenario-Ratones, which holds more than 15 Mt-LCE of drainable mineral resources

On the occasion of a meeting between Christel Bories, Chair and CEO of Eramet, and President Javier Milei during Argentina Week in Paris, Eramet confirms its intention to apply for inclusion under Argentina’s RIGI framework to support the first expansion of Centenario-Ratones, reaffirming its long-term commitment to Argentina and its ambition to further develop its lithium activities in the country.

A first capital-efficient expansion, with a planned application under Argentina’s RIGI framework

Eramet announced in July plans for the first expansion of its Centenario-Ratones lithium operation in Salta Province, Argentina, through a brownfield project, following the completion of the project’s Pre-Feasibility Study.

The contemplated expansion would add 11 kt-LCE per year of lithium carbonate production capacity, on top of the existing 24 kt-LCE annual nameplate capacity. The project would represent a potential additional investment of around US$350 million, subject to final investment decision¹. This investment would be partly funded by cash generated by the existing plant. Detailed engineering studies are currently underway. The project has been designed to deliver a lower capital intensity while further strengthening the operation’s position within the first quartile of the global lithium industry cost curve.

Argentina is strengthening its position as a destination for long-term investment in critical minerals thanks to RIGI. This scheme offers tax, customs and foreign exchange incentives, together with regulatory stability for 30 years. By seeking inclusion under the RIGI regime, Eramet intends to align the next phase of Centenario-Ratones with Argentina’s efforts to attract investment, develop its lithium industry and strengthen its position in global critical-minerals supply chains.

Building on the successful ramp-up of Centenario-Ratones plant

Following the start of ramp-up in mid-2025, the Centenario-Ratones plant reached 90% of nameplate capacity in June 2026, in line with the project’s development plan and approximately one year after start-up. The operation is progressing towards a level close to 100% of nameplate capacity by the end of 2026.

From exploration to the development and successful ramp-up of the plant, Centenario-Ratones illustrates Eramet’s distinctive end-to-end expertise across the lithium value chain, combining geological and mining expertise, technological innovation and operational execution.

The ramp-up of Centenario-Ratones also represents a major industrial achievement for Argentina as the first full new generation Direct Lithium Extraction (DLE) facility operating at industrial scale outside China.

A long-term potential to be further developed

Beyond this initial expansion, Eramet continues to develop a comprehensive life of asset plan to further enhance the potential of Centenario-Ratones salar, one of the most promising salars of the ‘Lithium Triangle’. This world-class asset has drainable mineral resources exceeding 15 Mt-LCE, together with favourable geological conditions and secured access to freshwater resources, providing substantial potential for the long-term development of the asset.

Eramet has been developing its lithium activities in Argentina since 2011 and discovered the Centenario-Ratones salar in 2012. With a global investment of approximately US$950 million in the first 24 kt-LCE DLE plant, Centenario-Ratones is one of the largest French industrial investments in Argentina and has established Eramet as the first European company to produce lithium at industrial scale. The contemplated expansion would further strengthen this long-term industrial commitment and Eramet’s contribution to the development of Argentina’s lithium industry.

Christel Bories, Chair and CEO of Eramet:

« Through today’s announcement, Eramet reaffirms its ambition to further develop a leading, sustainable and competitive lithium platform in Argentina, contributing to local value creation while supporting the global energy transition. The successful ramp-up of our Centenario-Ratones plant provides a strong foundation for pursuing this ambition. Argentina has the resources and the industrial potential to become an increasingly important player in the global lithium industry. The greater visibility being created for long-term investors, notably through the RIGI, is an important factor in enabling companies such as Eramet to consider new investment and further development in Argentina. »

 ABOUT ERAMET         

Eramet transforms the Earth’s mineral resources to provide sustainable and responsible solutions to the growth of the industry and to the challenges of the energy transition.

Its employees are committed to this through their civic and contributory approach in all the countries where the mining and metallurgical group is present.

Manganese, nickel, mineral sands, lithium: Eramet recovers and develops metals that are essential to the construction of a more sustainable world.

As a privileged partner of its industrial clients, the Group contributes to making robust and resistant infrastructures and constructions, more efficient means of mobility, safer health tools and more efficient telecommunications devices.

Fully committed to the era of metals, Eramet’s ambition is to become a reference for the responsible transformation of the Earth’s mineral resources for living well together.

www.eramet.com

INVESTOR CONTACT Director of Investor Relations Sandrine Nourry-Dabi T. +33 1 45 38 37 02 sandrine.nourrydabi@eramet.com

PRESS CONTACT Media Relations Officer Nedjma Amrani T. +33 6 65 65 44 49 nedjma.amrani@eramet.com

---

¹ A final investment decision could be made by end-2027

Attachment

• 2026 10 01 – Centenario_Expansion_RIGI – PR EN VF

Gold, currently EVP of the SMB & Channel division, will lead the company’s revenue organization starting October 1, 2026

PETAH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) — Global-e Online Ltd. (Nasdaq: GLBE), the leading global e-commerce enablement platform powering the world’s most iconic brands, today announced that Tomer Gold, currently Executive Vice President of the company’s SMB & Channel division, will become Chief Revenue Officer, effective October 1, 2026. Gold brings extensive experience across Global-e’s commercial organization and a deep understanding of its customers, products, and global growth strategy. He will lead the company’s revenue organization as Global-e enters its next phase of growth.

Ran Fridman, Chief Revenue Officer, will leave the company after more than five years to pursue his next opportunity. During his tenure, Fridman helped scale the company’s commercial organization and supported its growth worldwide.

“As our first ever hired CRO, Ran played a pivotal role in scaling Global-e’s business and global outreach. We thank him for his valuable contribution to the company’s growth, and wish him great success in his new endeavor,” said Nir Debbi, President of Global-e. “We also wish Tomer much success in his new role as CRO. Given Tomer’s proven leadership abilities and his in-depth knowledge of Global-e’s organization and business lines, we are confident he will lead the company’s commercial organization to new heights.”

About Global-e

Global-e (Nasdaq: GLBE) is the world’s leading platform enabling and accelerating global, Direct-To-Consumer e-commerce. The chosen partner of over 1,500 brands and retailers across North America, EMEA and APAC, Global-e makes selling internationally as simple as selling domestically. The company enables merchants to increase the conversion of international traffic into sales by offering online shoppers in over 200 destinations worldwide a seamless, localized shopping experience. Global-e’s end-to-end e-commerce solutions combine best-in-class localization capabilities, big-data best-practice business intelligence models, streamlined international logistics and vast global e-commerce experience, enabling international shoppers to buy seamlessly online and retailers to sell to, and from, anywhere in the world. For more information, please visit: www.global-e.com.

Investor Contact:
Alan Katz
Global-e Investor Relations
IR@global-e.com

Press Contact:
Sarah Small
Headline Media
sarah@headline.media 
+1 (914) 336-4718

VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Finning International Inc. (TSX: FTT) (“Finning”, the “Company”, “we”, “our” or “us”) today announced the acquisition of John F Hunt Power Group Limited (“John F Hunt Power”).

John F Hunt Power is one of the UK’s larger specialist generator rental companies, with a strong industry brand built on delivering high-quality solutions and service, and a track record of profitable growth. John F Hunt Power operates nationwide, serving a substantial and diverse customer base across a broad range of industries, including industrial, healthcare, events and construction.

With 145 employees and a nationwide fleet of approximately 2,500 generator units supported by six strategically located depots, John F Hunt Power provides 24/7 coverage across the UK. In addition to its specialized generator rental offering, the company is recognized for its innovative Fuel as a Service solution, delivering a seamless end-to-end experience for customers.

“John F Hunt Power is a highly respected business with an outstanding track record of supporting customers with reliable, specialist power solutions. We are delighted to welcome the team to Finning.

The acquisition is a major step forward in our growth strategy, projected to more than triple our power rental revenue in the UK and Ireland while significantly expanding our power generation solutions capability. It strengthens our ability to support customers with a broader range of applications, larger projects and increasingly complex power requirements.

We are investing in a market with significant long-term growth potential, and this acquisition builds on the strong organic growth already being delivered by our business, accelerating our ambitions through additional scale, expertise and capability. This is an exciting opportunity to bring together complementary strengths, talented people and a shared commitment to customer support,” said Gary Megarrell, Managing Director, Finning UK & Ireland.

The acquisition was funded using existing liquidity and remains consistent with Finning’s disciplined capital allocation framework. The transaction is not expected to have a material impact on Finning’s combined revenue, earnings or balance sheet.

About Finning
Finning is the world’s largest Caterpillar dealer. Headquartered in Surrey, British Columbia, we sell and rent Caterpillar equipment and provide parts, service and performance solutions in Western Canada, Chile, Argentina, Bolivia, the United Kingdom, and Ireland. Since 1933, we have delivered unrivalled customer service and are committed to solving our customers’ toughest challenges.

Contact Information
Email: FinningIR@finning.com
www.finning.com

FORWARD-LOOKING INFORMATION DISCLAIMER

This news release contains information about our business outlook, objectives, plans, strategic priorities and other information that is not historical fact. Information we provide is forward-looking when we use what we know and expect today to give information about the future. All forward-looking information in this news release is subject to this disclaimer, including the assumptions and material risk factors referred to below. Forward-looking information in this news release includes, but is not limited to, the following: that the acquisition is projected to more than triple our power rental revenue in the UK and Ireland while significantly expanding our power generation solutions capability; our belief that the acquisition strengthens our ability to support customers with a broader range of applications, larger projects and increasingly complex power requirements; our belief that we are investing in a market with significant long term growth potential; our expectation that the acquisition will accelerate our ambitions through additional scale, expertise and capability; and our expectation that the acquisition will not have an overall material impact on our combined revenue, earnings or balance sheet. All such forward-looking information is made pursuant to the ‘safe harbour’ provisions of applicable Canadian securities laws.

Unless we indicate otherwise, forward-looking information in this news release reflects our expectations at the date of this news release. Except as may be required by Canadian securities laws, we do not undertake any obligation to update or revise any forward-looking information, whether due to new information, future events, or otherwise.

Forward-looking information, by its very nature, is subject to numerous risks and uncertainties and is based on a number of assumptions. This gives rise to the possibility that actual results could differ materially from the expectations expressed in or implied by such forward-looking information and that our business outlook, objectives, plans, strategic priorities and other information that is not historical fact may not be achieved. As a result, we cannot guarantee that any forward-looking information will materialize and no assurance can be given that our projections will result in sustained or improved financial performance, or that past performance is indicative of future results.

Forward-looking information is provided in this news release for the purpose of giving information about our current expectations and plans and allowing investors and others to get a better understanding of our operating environment. However, readers are cautioned that it may not be appropriate to use such forward-looking information for any other purpose.

Forward-looking information provided in this news release is based on assumptions that we believed were reasonable on the day the information was given, including our assumptions related the acquired business’ projected revenue. Some of the assumptions, risks and other factors which could cause results to differ materially from those expressed in the forward-looking information in this news release, are discussed in our current Annual Information Form (AIF) and in our most recent annual and quarterly management’s discussion and analysis (MD&A). We caution readers that any risks described in this news release, or in our MD&A or AIF are not the only ones that could impact us. Additional risks and uncertainties not currently known to us or that are currently deemed to be immaterial may also have a material adverse effect on our business, financial condition, or results of operations.

Suominen Corporation October 1, 2026, at 3:00 p.m. (EEST)

Suominen Oyj – Managers’ Transactions

____________________________________________

Person subject to the notification requirement

Name: Charles Héaulmé

Position: Chief Executive Officer

 Issuer: Suominen Oyj

LEI: 743700Z1BNFYR9PRDF52

Notification type: INITIAL NOTIFICATION

Reference number: 174870/6/6

____________________________________________

Transaction date: 2026-09-30

Outside a trading venue

Instrument type: SHARE

ISIN: FI0009010862

Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details

(1): Volume: 324000 Unit price: 0 N/A

Aggregated transactions (1):

Volume: 324000 Volume weighted average price: 0 N/A

____________________________________________

SUOMINEN CORPORATION

For further information, please contact:

Kimmo Raunio, CFO, tel. +358 10 214 3053

About Suominen Corporation 

Suominen manufactures nonwovens as roll goods for wipes and other applications. Our vision is to be the frontrunner for nonwovens innovation and sustainability. The end products made of Suominen’s nonwovens are present in people’s daily life worldwide. Suominen’s net sales in 2025 were EUR 412.4 million and we have almost 700 professionals working in Europe and in the Americas. Suominen’s shares are listed on Nasdaq Helsinki. Read more at www.suominen.fi.